Wave Life Sciences Ltd. Ordinary Shares (WVE)
Stock · NASDAQ · Health Care
$3.13as of 10/16/2026
Price chart
Active signals
WVE Signal Track Record
How signals performed across all stocks →What WVE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 39 | +5.3% | 56% | September 1, 2026 |
| Bollinger Band Breakdown | 21 | -1.2% | 43% | September 23, 2026 |
| Bollinger Band Breakout | 22 | -6.5% | 41% | July 2, 2026 |
| 200-Day Moving Average TouchActive now | 16 | +5.9% | 63% | October 29, 2025 |
| Any 20-session window (baseline) | -2.0% | 46% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About WVE
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 anti…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 317
- Website
- www.wavelifesciences.com/
Fundamentals
- 1-day range
- $3.78$4.07
- Market cap
- $1.19B
- P/E (trailing)
- —
- P/E (forward)
- -3.35
- EPS (trailing)
- $-1.09
- Dividend yield
- —
- Beta
- -1.46
- Avg. volume
- 3.05M
How Wave Life Sciences Ltd. Ordinary Shares Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
17 analyst ratings
Wave Life Sciences Ltd. Ordinary Shares Competitors
Chosen by industry and closest market cap.
- WVEWave Life Sciences Ltd. Ordinary Shares$3.13▼ 1.88%Market cap $1.19BP/E —$3.56$21.73
- SVRASavara Inc. Common Stock$4.45▼ 6.12%Market cap $1.19BP/E —$3.38$7.01
- ARDXArdelyx Inc. Common Stock$3.09▼ 5.50%Market cap $1.20BP/E —$3.06$8.4
- CRVSCorvus Pharmaceuticals Inc. Common Stock$9.52▼ 3.35%Market cap $1.17BP/E —$6.39$26.95
- MNKDMannKind Corporation Common Stock$3.04▼ 4.70%Market cap $1.24BP/E —$2.23$6.51
- ETONEton Pharmaceuticals Inc. Common Stock$50.31▼ 1.99%Market cap $1.26BP/E 133.39$14.27$66.37
- ANROAlto Neuroscience Inc. Common Stock$21.94▼ 3.01%Market cap $1.11BP/E —$5.23$37.48
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| WVE Wave Life Sciences Ltd. Ordinary Shares | $1.19B | — | $3.13 | ▼ 1.88% | $3.56$21.73 |
| SVRA Savara Inc. Common Stock | $1.19B | — | $4.45 | ▼ 6.12% | $3.38$7.01 |
| ARDX Ardelyx Inc. Common Stock | $1.20B | — | $3.09 | ▼ 5.50% | $3.06$8.4 |
| CRVS Corvus Pharmaceuticals Inc. Common Stock | $1.17B | — | $9.52 | ▼ 3.35% | $6.39$26.95 |
| MNKD MannKind Corporation Common Stock | $1.24B | — | $3.04 | ▼ 4.70% | $2.23$6.51 |
| ETON Eton Pharmaceuticals Inc. Common Stock | $1.26B | 133.39 | $50.31 | ▼ 1.99% | $14.27$66.37 |
| ANRO Alto Neuroscience Inc. Common Stock | $1.11B | — | $21.94 | ▼ 3.01% | $5.23$37.48 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- This Nike Analyst Turns Bearish; Here Are Top 5 Downgrades For FridayBenzinga · 9/25/2026
- This Yum Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For ThursdayBenzinga · 9/24/2026
- Wave Life Sciences Initiates Phase 2a Combination Trial of WVE-007 (GalNAc-siRNA) with Tirzepatide for ObesityYahoo · 9/23/2026
- This Autoliv Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayBenzinga · 9/23/2026
- JP Morgan Downgrades Wave Life Sciences to NeutralBenzinga · 9/23/2026
- Wave Life Sciences Starts Phase 2a Clinical Study Of WVE-007 To Treat ObesityBenzinga · 9/23/2026
- Wave Life Sciences Announces Appointment of Dr. Monika Vnuk as Chief Business OfficerYahoo · 9/22/2026
Insider Activity
Insider Actions →- Adrian Rawcliffe · August 12, 2026 · Sale12.7K @ $5.29
- Heidi L. Wagner · August 11, 2026 · Option Exercise7.0K @ $5.97
- Heidi L. Wagner · August 11, 2026 · Sale7.0K @ $6.01
- Ken Takanashi · August 11, 2026 · Sale3.9K @ $6.01
- Aik Na Tan · August 11, 2026 · Sale432 @ $6.01
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Wave Life Sciences to Present at Chardan Healthcare Conference
Wave Life Sciences announced it will present at Chardan’s 10th Annual Healthcare Conference. The presentation offers a chance to discuss recent developments and pipeline progress with investors and industry peers. This exposure arrives while the stock is near a key support level, and observers may look for any new information that could affect sentiment.
Wave Life Sciences to Present at Chardan Healthcare Conference. Wave Life Sciences announced it will present at Chardan’s 10th Annual Healthcare Conference. The presentation offers a chance to discuss recent developments and pipeline progress with investors and industry peers. This exposure arrives while the stock is near a key support level, and observers may look for any new information that could affect sentiment.